menu search

ALNY / Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues

Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues
Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration revenues. Read More
Posted: Nov 3 2023, 13:32
Author Name: Zacks Investment Research
Views: 072484

ALNY News  

Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues

By Zacks Investment Research
November 3, 2023

Alnylam (ALNY) Swings to Earnings in Q3 on Collaboration Revenues

Alnylam (ALNY) reports better-than-expected third-quarter 2023 results, beating both earnings and sales estimates on the back of higher collaboration more_horizontal

Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran

By Seeking Alpha
October 13, 2023

Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran

We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is more_horizontal

Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One

By Seeking Alpha
October 10, 2023

Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One

Despite a positive panel recommendation, the FDA rejected the Alnylam Pharmaceuticals, Inc. application to market Onpattro for ATTR-CM, citing a lack more_horizontal

Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro

By Zacks Investment Research
October 10, 2023

Alnylam (ALNY) Receives CRL for the Label Expansion of Onpattro

Alnylam's (ALNY) label expansion-seeking application for Onpattro, to treat transthyretin-mediated amyloidosis with cardiomyopathy, gets the FDA's CRL more_horizontal

Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma

By Yahoo Finance
October 9, 2023

Top stocks October 9, 2023: Tesla, Bristol Myers-Mirati, Alnylam Pharma

Tesla (TSLA) shares are in focus as China-made EV demand drops by 10%, affecting Model 3 and Y sales. Tesla's delivery and production data declined fr more_horizontal

Alnylam Stock Is Dropping on Surprising FDA Rejection

By Barrons
October 9, 2023

Alnylam Stock Is Dropping on Surprising FDA Rejection

Drugmaker Alnylam wanted to expand approval of its drug Onpattro, but the Food and Drug Administration rejected the application even after an outside more_horizontal

US FDA declines approval for expanded use of Alnylam's heart-disease drug

By Reuters
October 9, 2023

US FDA declines approval for expanded use of Alnylam's heart-disease drug

The U.S. Food and Drug Administration has declined to approve the expanded use of Alnylam Pharmaceuticals' drug to treat a rare and fatal heart diseas more_horizontal

Alnylam to scrap sNDA for patisiran after receiving FDA complete response letter

By Market Watch
October 9, 2023

Alnylam to scrap sNDA for patisiran after receiving FDA complete response letter

Alnylam Pharmaceuticals Inc. ALNY, -1.00% said Monday it would no longer pursue its supplemental new drug application (sNDA) for patisiran as a treatm more_horizontal


Search within

Pages Search Results: